SITE008-0142

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-08-05

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-16 (study day 54); relationship: Y

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-11-12 (study day 81); relationship: N

mild assessed

Grade 1 Anaemia — outcome: UNKNOWN; onset 2022-11-20 (study day 89); relationship: not assessed

severe serious assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-03 (study day 102); relationship: N; serious criteria: hospitalization

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-05-07 (study day 257); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-29 (study day 340); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-25 (study day 459); relationship: N

Data queries

No data queries.